Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Primary Immunodeficiency
How do you approach the decision between lentiviral gene therapy, enzyme-replacement therapy, or allogeneic hematopoietic stem-cell transplantation for managing patients with ADA-SCID?
Related Questions
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
Should the RSV vaccine be administered to pregnant mothers even if it is not seasonally circulating but they are 32-36 weeks pregnant?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
How often are you performing CT screening in CVID patients to screen for ILD?
Is there any genetic testing available for the CDHR3 receptor?
When a patient has CVID and is then diagnosed with lymphoma receiving ongoing chemotherapy, how do you manage the trough levels?
For patients with progessive CKD with comorbid conditions, do you adjust IVIG or switch to SCIG to prevent further progession in GFR reduction?
Would you consider the use of ruxolitinib for tumor fevers and leukocytosis?
Do you recommend weekly SQ immunoglobulin replacement for an asplenic patient who only responded to 4/23 pneumococcal serotypes after the Prevnar 20 vaccine?
